Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ANTHRACYCLINE-RESISTANT' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 95 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Campone, M; Fumoleau, P; Delecroix, V; Deporte-Fety, R; Perrocheau, G; Vernillet, L; Borg-Olivier, O; Louboutin, JP; Bissery, MC; Riva, A; Azli, N
      Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer

      ANNALS OF ONCOLOGY
    2. Hainsworth, JD; Burris, HA; Yardley, DA; Bradof, JE; Grimaldi, M; Kalman, LA; Sullivan, T; Baker, M; Erland, JB; Greco, FA
      Weekly docetaxel in the treatment of elderly patients with advanced breastcancer: A Minnie Pearl Cancer Research Network phase II trial

      JOURNAL OF CLINICAL ONCOLOGY
    3. Khayat, D; Chollet, P; Antoine, EC; Monfardini, S; Ambrosini, G; Benhammouda, A; Mazen, MF; Sorio, R; Borg-Olivier, O; Ramazeilles, C; Azli, N
      Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breastcancer

      JOURNAL OF CLINICAL ONCOLOGY
    4. Orlandi, L; Bertoli, G; Abolafio, G; Daidone, MG; Zaffaroni, N
      Effects of liposome-entrapped annamycin in human breast cancer cells: Interference with cell cycle progression and induction of apoptosis

      JOURNAL OF CELLULAR BIOCHEMISTRY
    5. Mehta, RS; Bornstein, R; Yu, IR; Parker, RJ; McLaren, CE; Nguyen, KP; Li, KT; Fruehauf, JP
      Breast cancer survival and in vitro tumor response in the extreme drug resistance assay

      BREAST CANCER RESEARCH AND TREATMENT
    6. Valero, V; Perez, E; Dieras, V
      Doxorubicin and taxane combination regimens for metastatic breast cancer: Focus on cardiac effects

      SEMINARS IN ONCOLOGY
    7. Dieras, V; Beuzeboc, P; Laurence, V; Pierga, JY; Pouillart, P
      Interaction between Herceptin((R)) and taxanes

      ONCOLOGY
    8. Kruijtzer, CMF; Verweij, J; Schellens, JHM; Beijnen, JH; Pronk, L; Bo, M; Lustig, V; van Tinteren, H; Mackay, M; Huinink, WWT
      Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: Results of a compassionate use program inThe Netherlands

      ANTI-CANCER DRUGS
    9. Vassilomanolakis, M; Koumakis, G; Barbounis, V; Demiri, M; Pateras, H; Efremidis, AP
      Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines

      ANNALS OF ONCOLOGY
    10. Munster, PN; Hudis, CA
      Role of taxanes in adjuvant therapy

      CANCER INVESTIGATION
    11. Burstein, HJ; Manola, J; Younger, J; Parker, LM; Bunnell, CA; Scheib, R; Matulonis, UA; Garber, JE; Clarke, KD; Shulman, LN; Winer, EP
      Docetaxel administered on a weekly basis for metastatic breast cancer

      JOURNAL OF CLINICAL ONCOLOGY
    12. Alexandre, J; Bleuzen, P; Bonneterre, J; Sutherland, W; Misset, JL; Guastalla, JP; Viens, P; Faivre, S; Chahine, A; Spielman, M; Bensmaine, A; Marty, M; Mahjoubi, M; Cvitkovic, E
      Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients

      JOURNAL OF CLINICAL ONCOLOGY
    13. Yamamoto, N; Tamura, T; Kamiya, Y; Sekine, I; Kunitoh, H; Saijo, N
      Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol

      JOURNAL OF CLINICAL ONCOLOGY
    14. Ojeifo, JO; Wu, AGG; Miao, YH; Herscowtiz, HB; Meehan, KR
      Docetaxel-induced mobilization of hematopoietic stem cells in a murine model: Kinetics, dose titration, and toxicity

      EXPERIMENTAL HEMATOLOGY
    15. Prince, HM; Toner, GC; Seymour, JF; Blakey, D; Gates, P; Eerhard, S; Chapple, P; Wall, D; Quinn, M; Juneja, S; Wolf, M; Januszewicz, EH; Richardson, G; Scarlett, J; Briggs, P; Brettell, M; Rischin, D
      Docetaxel effectively mobilizes peripheral blood CD34(+) cells

      BONE MARROW TRANSPLANTATION
    16. Shin, E; Ishitobi, M; Hiraoia, M; Kazumasa, F; Hideyuki, M; Nishisho, I; Toshiro, S; Yasunori, H; Tosimasa, T
      Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer

      ANTICANCER RESEARCH
    17. Salminen, E; Bergman, M; Huhtala, S; Jekunen, A; Ekholm, E
      Docetaxel, a promising novel chemotherapeutic agent in advanced breast cancer

      ANTICANCER RESEARCH
    18. Wang, F; Jiang, XP; Yang, DC; Elliott, RL; Head, JF
      Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: Evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells

      ANTICANCER RESEARCH
    19. Rivera, E; Holmes, FA; Frye, D; Valero, V; Theriault, RL; Booser, D; Walters, R; Buzdar, AU; Dhingra, K; Fraschini, G; Hortobagyi, GN
      Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy

      CANCER
    20. Bonneterre, J; Spielman, M; Guastalla, JP; Marty, M; Viens, P; Chollet, P; Roche, H; Fumoleau, P; Mauriac, L; Bourgeois, H; Namer, M; Bergerat, JP; Misset, JL; Trandafir, L; Mahjoubi, M
      Efficacy and safety of docetaxel (Taxotere (TM)) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience

      EUROPEAN JOURNAL OF CANCER
    21. Misset, JL; Dieras, V; Gruia, G; Bourgeois, H; Cvitkovic, E; Kalla, S; Bozec, L; Beuzeboc, P; Jasmin, C; Aussel, JP; Riva, A; Azli, N; Pouillart, P
      Dose-finding study of docetaxel and doxorubicin in first-line treatment ofpatients with metastatic breast cancer

      ANNALS OF ONCOLOGY
    22. O'Brien, MER; Leonard, RC; Barrett-Lee, PJ; Eggleton, SPH; Bizzari, JP
      Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere (R)) in the UK

      ANNALS OF ONCOLOGY
    23. Ouar, Z; Lacave, R; Bens, M; Vandewalle, A
      Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells

      CELL BIOLOGY AND TOXICOLOGY
    24. Miller, KD; Sledge, GW
      Taxanes in the treatment of breast cancer: A prodigy comes of age

      CANCER INVESTIGATION
    25. Cortazar, P; Johnson, BE
      Review of the efficacy of individualized chemotherapy selected by in vitrodrug sensitivity testing for patients with cancer

      JOURNAL OF CLINICAL ONCOLOGY
    26. Miller, KD; McCaskill-Stevens, W; Sisk, J; Loesch, DM; Monaco, F; Seshadri, R; Sledge, GW
      Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group

      JOURNAL OF CLINICAL ONCOLOGY
    27. Alexopoulos, CG; Rigatos, G; Efremidis, AP; Papacharalambous, A; Alexopoulos, A; Vassilomanolakis, M; Patila, E
      A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    28. Levine, EG; Cirrincione, CT; Szatrowski, TP; Canellos, G; Norton, L; Henderson, IC
      Phase II trial of topotecan in advanced breast cancer - A Cancer and Leukemia Group B study

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    29. Weaver, CH; Schwartzberg, LS; Zhen, B; Franco, C; Moore, M; Smith, R; White, L; Van Amburg, A; Hazelton, B; Buckner, CD
      Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of3 vs 4 g/m(2) of CY

      BONE MARROW TRANSPLANTATION
    30. Culine, S
      Taxotere as second-line chemotherapy for metastatic breast cancer.

      REVUE DE MEDECINE INTERNE
    31. Kucuk, O; Pandya, KJ; Skeel, RT; Hochster, H; Abeloff, MD
      Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185)

      BREAST CANCER RESEARCH AND TREATMENT
    32. Burris, HA
      Single-agent docetaxel (Taxotere) in randomized phase III trials

      SEMINARS IN ONCOLOGY
    33. Hortobagyi, GN
      Recent progress in the clinical development of docetaxel (Taxotere)

      SEMINARS IN ONCOLOGY
    34. Trudeau, ME
      Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer

      SEMINARS IN ONCOLOGY
    35. Hainsworth, JD; Burris, HA; Greco, FA
      Weekly administration of docetaxel (Taxotere): Summary of clinical data

      SEMINARS IN ONCOLOGY
    36. Piccart-Gebhart, M
      What can be expected from the next generation of adjuvant breast cancer treatment?

      SEMINARS IN ONCOLOGY
    37. Wenzel, C; Schmidinger, M; Locker, GJ; Taucher, S; Gnant, M; Jakesz, R; Steger, GG
      Clinical phase II evaluation of the combination therapy with Docetaxel andEpidoxorubicin in the neoadjuvant, cytostatic treatment on patients with primary breast cancer (T1-4, N0-2, M0)

      WIENER KLINISCHE WOCHENSCHRIFT
    38. Blum, JL
      Xeloda (R) in the treatment of metastatic breast cancer

      ONCOLOGY
    39. LAMB HM; WISEMAM LR
      DOCETAXEL - A PHARMACOECONOMIC REVIEW OF ITS USE IN THE TREATMENT OF METASTATIC BREAST-CANCER

      PharmacoEconomics
    40. ESPIE M; CUVIER C; GORINS A; MARTY M
      TAXANES IN THE TREATMENT OF BREAST AND OVARIAN CANCERS - CURRENT INDICATIONS AND RESULTS

      Contraception fertilite sexualite
    41. TANKANOW RM
      DOCETAXEL - A TAXOID FOR THE TREATMENT OF METASTATIC BREAST-CANCER

      American journal of health-system pharmacy
    42. ARCHER CD; LOWDELL C; SINNETT HD; ENGLISH J; KHAN S; COOMBES RC
      DOCETAXEL - RESPONSE IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR CHEMOTHERAPY REGIMES FOR METASTATIC BREAST-CANCER

      European journal of cancer
    43. Brown, RE; Hutton, J
      Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients

      ANTI-CANCER DRUGS
    44. Espie, M
      New therapeutic strategies for breast cancer

      PRESSE MEDICALE
    45. HAINSWORTH JD; BURRIS HA; ERLAND JB; THOMAS M; GRECO FA
      PHASE-I TRIAL OF DOCETAXEL ADMINISTERED BY WEEKLY INFUSION IN PATIENTS WITH ADVANCED REFRACTORY CANCER

      Journal of clinical oncology
    46. VALERO V; JONES SE; VONHOFF DD; BOOSER DJ; MENNEL RG; RAVDIN PM; HOLMES FA; RAHMAN Z; SCHOTTSTAEDT MW; ERBAN JK; ESPARZAGUERRA L; EARHART RH; HORTOBAGYI GN; BURRIS HA
      A PHASE-II STUDY OF DOCETAXEL IN PATIENTS WITH PACLITAXEL-RESISTANT METASTATIC BREAST-CANCER

      Journal of clinical oncology
    47. BRUNO R; HILLE D; RIVA A; VIVIER N; HUINNINK WWTB; VANOOSTEROM AT; KAYE SB; VERWEIJ J; FOSSELLA FV; VALERO V; RIGAS JR; SEIDMAN AD; CHEVALLIER B; FUMOLEAU P; BURRIS HA; RAVCLIN PM; SHEINER LB
      POPULATION PHARMACOKINETICS PHARMACODYNAMICS OF DOCETAXEL IN PHASE-IISTUDIES IN PATIENTS WITH CANCER/

      Journal of clinical oncology
    48. Spiridonidis, CH; Laufman, LR; Jones, J; Rhodes, VA; Wallace, K; Nicol, S
      Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies

      JOURNAL OF CLINICAL ONCOLOGY
    49. JACKISCH C
      CURRENT DEVELOPMENTS IN THE APPLICATION OF DOCETAXEL (TAXOTERE(R)) INGYNECOLOGIC ONCOLOGY

      Medizinische Klinik
    50. IINO Y; YOKOE T; SUGAMATA N; MAEMURA M; TAKEI H; HORIGUCHI J; TAKEYOSHI I; OHWADA S; MORISHITA Y; KUSABA T; ISHIDA T; YOKOMORI T; FUJII T; ENDO K; SHIOZAKI H; AIBA S; TAKANO A; KISHI S
      A COMBINATION CHEMOENDOCRINE THERAPY OF MITOXANTRONE, DOXIFLURIDINE, AND MEDROXYPROGESTERONE ACETATE FOR ANTHRACYCLINE-RESISTANT ADVANCED BREAST-CANCER

      Cancer chemotherapy and pharmacology
    51. Vredenburgh, J; Fishman, R; Coniglio, D; Matters, L; Elkordy, M; Ross, M; Hussein, A; Rubin, P; Gilbert, C; Petros, W; Peters, WP
      The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    52. NIETO Y; MARTIN M; ALONSO JL; CASADO A; AYALA F; LOPEZMARTIN JA; RODRIGUEZLESCURE A; DIAZRUBIO E
      WEEKLY CONTINUOUS-INFUSION OF 5-FLUOROURACIL WITH ORAL LEUCOVORIN IN METASTATIC BREAST-CANCER PATIENTS WITH PRIMARY RESISTANCE TO DOXORUBICIN

      Breast cancer research and treatment
    53. BEAR HD
      INDICATIONS FOR NEOADJUVANT CHEMOTHERAPY FOR BREAST-CANCER

      Seminars in oncology
    54. Hortobagyi, G
      An expanding role for docetaxel

      SEMINARS IN ONCOLOGY
    55. Dieras, V
      Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer

      SEMINARS IN ONCOLOGY
    56. Pagani, O
      Taxoids in combination with epirubicin: The search for improved outcomes in breast cancer

      SEMINARS IN ONCOLOGY
    57. Ando, M; Watanabe, T; Sasaki, Y; Ying, DF; Omuro, Y; Katsumata, N; Narabayashi, M; Tokue, Y; Fujii, H; Igarashi, T; Wakita, H; Ohtsu, T; Itoh, K; Adachi, I; Taguchi, T
      A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer

      BRITISH JOURNAL OF CANCER
    58. VANVAERENBERGH W; PARIDAENS R; THOMAS J; WILDIERS J; VANOOSTEROM A
      DOCETAXEL IS A POTENT CYTOTOXIC DRUG IN THE TREATMENT OF ADVANCED BREAST-CANCER

      Acta Clinica Belgica
    59. KRAYNAK MA
      PHARMACEUTICAL ASPECTS OF DOCETAXEL

      American journal of health-system pharmacy
    60. YEE GC
      COST-UTILITY ANALYSIS OF TAXANE THERAPY

      American journal of health-system pharmacy
    61. FUMOLEAU P
      EFFICACY AND SAFETY OF DOCETAXEL IN CLINICAL-TRIALS

      American journal of health-system pharmacy
    62. CLEMONS M; LEAHY M; VALLE J; JAYSON G; RANSON M; HOWELL A
      REVIEW OF RECENT TRIALS OF CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - THE TAXANES

      European journal of cancer
    63. RUBENS RD
      THE ROLE OF DOCETAXEL IN IMPROVING TREATMENT OUTCOMES IN ADVANCED BREAST-CANCER

      European journal of cancer
    64. RAVDIN PM
      REFLECTIONS ON THE DEVELOPMENT OF RESISTANCE DURING THERAPY FOR ADVANCED BREAST-CANCER - IMPLICATIONS OF HIGH-LEVELS OF ACTIVITY OF DOCETAXEL IN ANTHRACYCLINE-RESISTANT BREAST-CANCER PATIENTS

      European journal of cancer
    65. DIERAS V; FUMOLEAU P; KALLA S; MISSET JL; AZLI N; POUILLART P
      DOCETAXEL IN COMBINATION WITH DOXORUBICIN OR VINORELBINE

      European journal of cancer
    66. DINCALCI M
      DIFFERENCES IN DOCETAXEL AND PACLITAXEL ACTIVITY IN RESISTANT TUMOR-CELLS WHICH EXPRESS MRP - NEED OF COMPARATIVE CLINICAL-TRIALS IN RESISTANT PATIENTS

      Annals of oncology
    67. KIMMICK G; MUSS HB
      BREAST-CANCER IN OLDER WOMEN

      Clinics in geriatric medicine
    68. PICCART MJ; KLIJN J; PARIDAENS R; NOOIJ M; MAURIAC L; COLEMAN R; BONTENBAL M; AWADA A; SELLESLAGS J; VANVRECKEM A; VANGLABBEKE M
      CORTICOSTEROIDS SIGNIFICANTLY DELAY THE ONSET OF DOCETAXEL-INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER

      Journal of clinical oncology
    69. MCCAFFREY JA; HILTON S; MAZUMDAR M; SADAN S; KELLY WK; SCHER HI; BAJORIN DF
      PHASE-II TRIAL OF DOCETAXEL IN PATIENTS WITH ADVANCED OR METASTATIC TRANSITIONAL-CELL CARCINOMA

      Journal of clinical oncology
    70. ANTOINE EC; RIXE O; AUCLERC G; WEIL M; KHAYAT D
      DOCETAXEL - A REVIEW OF ITS ROLE IN BREAST-CANCER-TREATMENT

      American journal of clinical oncology
    71. GOLDSPIEL BR
      CLINICAL OVERVIEW OF THE TAXANES

      Pharmacotherapy
    72. WEAVER CH; WEST WH; SCHWARTZBERG LS; ALBERICO T; LEFF R; GRECO FA; HAINSWORTH J; BIRCH R; MCANENY B; MAGEE M; RAEFSKY E; KALMAN L; BUCKNER CD
      INDUCTION, MOBILIZATION OF PERIPHERAL-BLOOD STEM-CELLS (PBSC), HIGH-DOSE CHEMOTHERAPY AND PBSC INFUSION IN PATIENTS WITH UNTREATED STAGE-IVBREAST-CANCER - OUTCOMES BY INTENT TO TREAT ANALYSES

      Bone marrow transplantation
    73. CALCABRINI A; VILLA AM; MOLINARI A; DOGLIA SM; ARANCIA G
      INFLUENCE OF N-METHYLFORMAMIDE ON THE INTRACELLULAR-TRANSPORT OF DOXORUBICIN

      European journal of cell biology
    74. VONHOFF DD
      THE TAXOIDS - SAME ROOTS, DIFFERENT DRUGS

      Seminars in oncology
    75. VALERO V
      DOCETAXEL AS SINGLE-AGENT THERAPY IN METASTATIC BREAST-CANCER - CLINICAL EFFICACY

      Seminars in oncology
    76. KHAYAT D; ANTOINE E
      DOCETAXEL IN COMBINATION CHEMOTHERAPY FOR METASTATIC BREAST-CANCER

      Seminars in oncology
    77. DANDREA GM; SEIDMAN AD
      DOCETAXEL AND PACLITAXEL IN BREAST-CANCER THERAPY - PRESENT STATUS AND FUTURE-PROSPECTS

      Seminars in oncology
    78. ROWINSKY EK
      THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

      Annual review of medicine
    79. HAINSWORTH JD; JOLIVET J; BIRCH R; HOPKINS LG; GRECO FA
      MITOXANTRONE, 5-FLUOROURACIL, AND HIGH-DOSE LEUCOVORIN (NFL) VERSUS INTRAVENOUS CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL (CMF) INFIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST-CARCINOMA

      Cancer
    80. LAUNOIS RJ; REBOULMARTY JM; BONNETERRE J
      A MEDICO-ECONOMIC ANALYSIS OF 2ND-LINE CH EMOTHERAPY IN METASTATIC BREAST-CANCER - DOCETAXEL VERSUS PACLITAXEL VERSUS VINORELBINE

      Bulletin du cancer
    81. SHAPIRO JD; MILLWARD MJ; RISCHIN D; DAVISON JD; MICHAEL M; FRANCIS PA; GANJU V; TONER GC
      ACTIVITY AND TOXICITY OF DOCETAXEL (TAXOTERE(R)) IN WOMEN WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER

      Australian and New Zealand Journal of Medicine
    82. HUTTON J; BROWN R; BOROWITZ M; ABRAMS K; ROTHMAN M; SHAKESPEARE A
      A NEW DECISION-MODEL FOR COST-UTILITY COMPARISONS OF CHEMOTHERAPY IN RECURRENT METASTATIC BREAST-CANCER

      PharmacoEconomics
    83. LAUNOIS R; REBOULMARTY J; HENRY B; BONNETERRE J
      A COST-UTILITY ANALYSIS OF 2ND-LINE CHEMOTHERAPY IN METASTATIC BREAST-CANCER - DOCETAXEL VERSUS PACLITAXEL VERSUS VINORELBINE

      PharmacoEconomics
    84. VERMORKEN JB; HUININK WWT
      CHEMOTHERAPY OF ADVANCED BREAST-CANCER - THE PLACE OF ACTIVE NEW DRUGS

      Breast
    85. BUZDAR AU; HORTOBAGYI GN; FRYE D; VALERO V
      2ND-LINE CHEMOTHERAPY FOR METASTATIC BREAST-CANCER INCLUDING QUALITY-OF-LIFE ISSUES

      Breast
    86. PICCART M
      TREATMENT OF ADVANCED BREAST-CANCER - CURRENT STATUS

      Anti-cancer drugs
    87. FUMOLEAU P
      TREATMENT OF PATIENTS WITH LIVER METASTASES

      Anti-cancer drugs
    88. HUAN SD; YAU JC; TOMIAK E; GOEL R; CRIPPS C; GERTLER SZ; PROSSER IA; STEWART DJ
      HYDROXYUREA DID NOT ENHANCE THE CLINICAL-RESPONSE TO VINBLASTINE IN PATIENTS WITH ANTHRACYCLINE-RESISTANT METASTATIC BREAST-CANCER

      Tumori
    89. GHAUHARALI RI; WESTERHOFF HV; DEKKER H; LANKELMA J
      SATURABLE P-GLYCOPROTEIN KINETICS ASSAYED BY FLUORESCENCE STUDIES OF DRUG EFFLUX FROM SUSPENDED HUMAN KB8-5 CELLS

      Biochimica et biophysica acta. Biomembranes
    90. LEMIEUX P; PAGE M
      SENSITIVITY OF MULTIDRUG-RESISTANT MCF-7 CELLS TO A TRANSFERRIN-DOXORUBICIN CONJUGATE

      Anticancer research
    91. MESCHINI S; MOLINARI A; CALCABRINI A; CITRO G; ARANCIA G
      INTRACELLULAR-LOCALIZATION OF THE ANTITUMOR DRUG ADRIAMYCIN IN LIVINGCULTURED-CELLS - A CONFOCAL MICROSCOPY STUDY

      Journal of Microscopy
    92. MORIYAMA Y; MANABE T; YOSHIMORI T; TASHIRO Y; FUTAI M
      ATP-DEPENDENT UPTAKE OF ANTINEOPLASTIC AGENTS BY ACIDIC ORGANELLES

      Journal of Biochemistry
    93. ARANCIA G; MOLINARI A; CALCABRINI A; CITRO G; VILLA AM; VERDINA A; ZUPI G
      EFFECTS OF SEQUENTIAL COMBINATIONS OF N-METHYLFORMAMIDE WITH ADRIAMYCIN ON CULTURED MELANOMA-CELLS (M14)

      Experimental and molecular pathology
    94. SOGNIER MA; ZHANG Y; EBERLE RL; SWEET KM; ALTENBERG GA; BELLI JA
      SEQUESTRATION OF DOXORUBICIN IN VESICLES IN A MULTIDRUG-RESISTANT CELL-LINE (LZ-100)

      Biochemical pharmacology
    95. SCHUURHUIS GJ; VANHEIJNINGEN THM; CERVANTES A; PINEDO HM; DELANGE JHM; KEIZER HG; BROXTERMAN HJ; BAAK JPA; LANKELMA J
      CHANGES IN SUBCELLULAR DOXORUBICIN DISTRIBUTION AND CELLULAR ACCUMULATION ALONE CAN LARGELY ACCOUNT FOR DOXORUBICIN RESISTANCE IN SW-1573 LUNG-CANCER AND MCF-7 BREAST-CANCER MULTIDRUG-RESISTANT TUMOR-CELLS

      British Journal of Cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/08/20 alle ore 14:52:19